summari ew host annual investor meet decemb
overal believ meet reinforc strong near-term
long-term outlook compani specif ew expect
favor low-risk data american colleg
cardiolog meet march believ
catalyst broader transcathet aortic valv replac
tavr market addit ew provid number posit
updat transcathet heart valv pipelin
noteworthi pipelin updat view sapien ultra
approv remain track around year-end european
approv pascal mitral repair devic expect
sapien pivot trial expect start late
base recent posit clinic data coapt expect
result ew updat long-term tavr
transcathet mitral tricuspid tmtt market estim
compani expect combin market transcathet heart
valv therapi reach repres compound-annual-growth-rate
regard guidanc
underli overal sale guidanc includ
tavr guidanc bracket estim consensu may
view slightli aggress investor midpoint
ep guidanc in-lin consensu
slightli better estim mainli due lower tax
rate despit investor concern tavr guidanc expect
stock react favor posit commentari
well encourag pipelin long-term outlook
figur summari ew guidanc vs street
expect figur ew pipelin opportun
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani data secur llc estim reuter
guidanc re-affirmed investor meet ew re-affirmed guidanc provid
call octob recal ew sale adj ep guidanc current stand higher-end
guidanc rang underli report respect
outlook divis also unchang thvt sale expect come toward higher-end
rang around underli shvt surgic heart valv therapi sale
expect toward higher-end underli manag expect critic
care cc sale toward higher-end guidanc rang exceed
underli growth target addit ew re-affirmed guidanc gross margin item
free cash flow fx foreign exchang
guidanc overal in-lin expect ew expect sale
underli growth compar estim underli
growth consensu underli growth midpoint underli
growth guidanc close estim consensu expect ew guid underli
growth bottom-lin ep guidanc slightli better expect ew ep guidanc
compar estim consensu midpoint ep
guidanc in-lin consensu expect ew guid adj ep
tavr guidanc also better expect guidanc transcathet aortic valv replac
tavr underli growth versu estim
underli growth importantli ew expect favor result march approv
low-risk late ew also guid transcathet mitral tricuspid tmtt revenu
vs estim math tmtt add almost point growth surgic
structur heart formerli shvt ew expect sale underli growth vs
critic ew expect sale underli growth
versu
guidanc item tax rate lower expect compani expect gross margin
vs estim ew expect sg vs estim
expect sale vs estim wed note acceler vs
guidanc sale fund numer on-going clinic studi ew expect oper
margin vs estim tax rate expect includ
estim etb excess tax benefit impact compar tax rate estim free
cash flow expect vs estim ew expect cap ex grow
million million ew anticip fx headwind
roughli top-lin next year compar estim headwind
model figur summari ew guidanc
long-term financi outlook today event ew provid high-level thought
compani financi outlook top-lin manag expect produc consider higher
organ growth industri averag regard gross margin mix effici expect
improv long-term gross margin though given amount new product introduct anticip
come yearsw suspect gross margin improv rel modest percent
sale expect declin vs level long-term sg spend expect remain
compar percentag sale basi put compon togeth yield
modest oper margin expans accord ew tax rate front manag expect
long-term tax rate increas vs expect level due less predict relat
stock option account potenti polici chang
long-term market estim posit ew announc today first time expect
global transcathet valv opportun reach includ roughli market
estim tavr mitral tricuspid use market estim impli
compound-annual-growth-rate transcathet valv includ low-teen growth tavr low growth
mitral tricuspid recal past compani guid tavr market
transcathet mitral tricuspid market
long-term tavr outlook updat longer term ew estim tavr
world-wide market opportun driven expans new indic
increas therapi awar advanc technolog recal ew previou long-term
tavr outlook call ww market given early-tavr ew asymptomat trial
expect complet enrol featur two-year follow-up time-frame
suspect ew market estim includ modest contribut asymptomat
ew guid tavr growth manag guid underli tavr growth
compar estim guidanc also slightli ahead
expect tavr guidanc manag note tavr growth expect back-end
load acceler throughout year given number move piec next year regard new
indic product launch competit litigationew outlin key assumpt includ
guidanc includ ww mid-teen market growth low-risk data american colleg
cardiolog march fda approv late new competit lotu come mid-
year portico late result modest share loss modest asp declin full-year
benefit sapien ultra signific impact litig sens ew
tavr guidanc may view slightli aggress investor
low-risk data expect favor data yet un-blind ew said expect favor
result march fda approv expect late manag optim
base part intermediate-risk data show low rate mortal sapien
clear ew suggest data show superior tavr manag note
design non-inferior studi said see chanc low risk
trial show ew sapien superior surgic aortic valv replac savr primari
endpoint regard potenti contribut low-risk ew said expect major
impact occur fda approv reimburs expect late howev manag
acknowledg border-lin low-risk patient could end treat tavr follow
result provid data posit
 approv sapien ultra remain track year-end clinic
strategi yet disclos ew sapien ultra manag note approv still
expect around end ou ew implement control launch strategi ultra excl
germani ultra enjoin regard ew self-expand valv centera manag
note investig devic exempt trial commenc octob enrol
like complet europ control commerci launch centera remain underway
early-tavr expect complet enrol today event manag provid
updat early-tavr evalu use tavr patient serv asymptomat aortic
stenosi ew note patient patient trial enrol date
manag expect fulli enrol trial point studi featur primari endpoint
two-year lead us believ could see approv point
transcathet mitral tricuspid therapi tmtt
ew expect global tmtt opportun reach ew updat long-term tmtt
market forecast compar ew previou expect
ew guid sale contribut ahead
estim manag comment pascal expect launch europ
mid-year expect provid greater contribut tmtt revenu cardioband manag
call coapt potenti tailwind transcathet mitral market convers ew
highlight competit clinic trial cardioband suppli transit like headwind
pascal updat posit ce mark time track importantli ew said time remain track
pascal receiv ce mark approv specif manag expect commenc
european launch mid-year manag note eu roll-out thought focus
physician train interpret control launch addit ew said pascal ce mark
data expect present either march europcr may ew note
clasp iid dmr pivot trial enrol clasp iif fmr pivot trial expect
initi late
cardioband suppli constraint expect improv throughout activ paus suppli
constraint hamper commerci adopt cardioband europ manag expect see
progress improv suppli front work transit product
israel ew said key focu cardioband improv procedur time clinic front
ew paus activ pivot studi evalu trial design light coapt result recal
ew random cardioband versu gdmt guidelin direct medic therapi
sapien move pivot late evoqu human transcathet mitral
valv replac tmvr front ew remain commit transsept strategi sapien
recent unveil evoqu biggest tmvr highlight view announc sapien
expect begin pivot studi late ew comment implant
patient good result wed note patient ef earli feasibl studi data present tct
transcathet cardiovascular past septemb strong regard evoqu
manag said done multipl success human case platform move forward
continu earli feasibl studi
notabl tricuspid updat regard ew tricuspid therapi notabl updat view
activ tr pivot trial cardioband tricuspid expect initi late pascal
tricuspid ef enrol forma remain continu ef updat devic
surgic structur heart growth expect driven inspiri ew expect deliv
underli revenu growth surgic structur heart busi
compani guidanc outlook surpris given continu tavr convers
 europ estim call ew surgic structur heart growth underli
bracket compani guidanc rang ew expect growth
driven continu adopt inspiri growth region tavr less
inspiri expect key growth driver ew launch inspiri valv us europ
japan earlier year strong initi commerci traction inspiri first surgic valv
design potenti futur valve-in-valv viv procedur featur resilia tissu extend
durabl make product especi attract younger activ patient
manag expect valv key driver segment growth beyond
konect launch europ konect system first ready-to-
implant tissu valv conduit help simplifi complex case involv aortic root well aortic valv
replac offer altern surgeon use multipl product singl off-the-shelf system
potenti reduc oper time system expect launch us europ
initi annual address popul patient per ew
harpoon devic re-launch europ ew recent complet review
harpoon technolog paus commerci roll-out europ shortli receiv ce mark
approv evalu hand case synthet chord ruptur seen ce mark studi ew found
ruptur result undu tension chord could rectifi proper techniqu
train devic modif requir ew expect begin treat patient europ
conduct post-market studi part relaunch manag note
expect minim sale impact
hemospher expect drive critic cc growth ew guid cc sale
underli compar estim million ew cc guidanc
repres deceler vs guidanc ew view increas hemospher platform
adopt improv util asia key growth driver cc next year manag
comment plan launch acumen iq technolog predict softwar design
prevent low blood pressur event hemospher platform eu ew
acknowledg long convers cycl slow adopt curv new technolog potenti
headwind busi
ew guidanceexpect guidanceour estimateconsensusreport sale sale sale growthnanananasurg structur sale sale profit interest share tax rate guidanc includ estim etb benefit compani report secur llc estim factset medic technolog
areaeventev timingpotenti sale contribut tavr indication/geograph expansionlow-risk indic fda data releas moder hf enrol completetbdearly-tavr asymptomat enrol devicessapien ultrac launchy pulmon alterrau replac repairevoqueiniti mark trial starttbdc feasibl pivot triallat mreu enrol mark trial complet dmr start clasp fmr start clasp iif late repairformaresum marktbdcardioband trce late secur llc estim ew option buysourc compani report clinicaltri gov secur llc estim corpor
price target nc
price target assum ep estim risk includ greater
share loss model delay mitral program neg clinic data
believ upcom data pipelin product help ew address new competit
transcathet mitral valv opportun signific catalyst
irvin california -base edward lifesci ew develop manufactur market product
design heart valv diseas cardiac surgeri critic care edward revenu reach
billion come transcathet heart valv therapi thv busi ew
player transcathet heart valv therapi market
